This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Vanderbilt University School of Medicine (VSOM) and the American Association for Cancer Research (AACR). VSOM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Vanderbilt University School of Medicine designates this educational activity for a maximum of 54 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
2007 AACR Annual Meeting Statement of Educational Need, Target Audience, and Learning Objectives
New technology and the resulting explosion in biological and genetic information have led to a significantly improved understanding of cancer development and progression, with major implications for cancer prevention, diagnosis, and treatment. By participating in the AACR Annual Meeting 2007, translational and clinical investigators and physicians will better understand the contributions of laboratory research to drug development and patient care, to the design and conduct of clinical research protocols, the epidemiological implications of cancer incidence, and the translation of the findings of laboratory research immediately for the benefit and care of the cancer patient. Through this participation of translational and clinical investigators and physicians, laboratory researchers will obtain a better understanding of the wider context of their research and of the particular clinical problems that regularly confront physicians.
This Annual Meeting is directed towards scientists and clinicians engaged in all aspects of clinical investigations pertaining to human cancer as well as the scientific disciplines of cellular, molecular, and tumor biology; carcinogenesis; chemistry; developmental biology and stem cells; endocrinology; epidemiology and biostatistics; experimental/molecular therapeutics; immunology; and radiobiology/radiation oncology; imaging; prevention and survivorship research.
After participating in this CME activity, participants should be able to:
- Demonstrate a clear understanding of the latest research findings in all areas of cancer research and how this research will impact future decision making in the detection, diagnosis, treatment, and prevention of cancer;
- Explain the integration of information from the basic and translational sciences to drug development, clinical research, and the application of new findings;
- Analyze the epidemiological implications of cancer incidence;
- Identify the importance of technological advances and their use in accelerating research progress;
- Apply the presented information and research to expedite the development of detection, prevention, and treatment strategies to reduce cancer incidence and mortality; and
- Formulate new strategies that will further scientific and clinical research efforts towards the prevention and early detection of cancer.
It is the policy of VSOM that the information presented at VSOM-sponsored CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, VSOM and the AACR will provide information that Program Committee members, speakers, and staff have disclosed about financial relationships they have with commercial entities that produce or market products or devices related to the content of this CME activity. This disclosure information will be made available in the Proceedings Supplement of this conference. In addition, off-label and investigational uses will be identified when mentioned.
Claiming CME Credit
The deadline for the submission of requests for credit for CME has elapsed. Please contact the AACR Office of CME at email@example.com or (215) 440-9300 with further inquiries.
Acknowledgment of Commercial Support
Supporters of this activity are listed in the Final Program.